TACSTD2 and breast cancer: While there were no reports on the association of TROP2 and basal markers in breast cancer, one study of lung adenocarcinoma found that the EGFR mutant was in 54% of the TROP2 low group and 46% of the TROP2 high group, but this was not statistically significant (p = 0.26) [32].